Xin Chen

Xin Chen

Auto-generated profile, based on publicly available information

Xin Chen

Hubei Selenium and Human Health Institute, the Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, Hubei, People’s Republic of China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2023 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
XZXing Zhong
Xing Zhong
RHRui Huang
Rui Huang
XCXin Chen
Xin Chen
YLYuhua Lei
Yuhua Lei
Background: Engeletin (ENG) is a natural flavonoid compound known for its diverse physiological and pharmacological effects, such as anti-inflammatory, antioxidant, and immunomodulatory properties. It has garnered significant attention as a promising candidate for drug development. Objective: This article aims to comprehensively review the clinical application, pharmacological action, and potential mechanisms of ENG, while exploring its prospects in clinical pharmacology. Methods: We conducted a systematic search of PubMed, Science Direct, Google Scholar, Web of Science, Scopus, and MEDLINE for a thorough review of high-quality articles on the source, extraction, and application of ENG, or the primary active ingredient for improving bodily injuries. Results: ENG exhibits significant potential in treating a variety of diseases across different systems, attributed to its anti-inflammatory, antioxidant, anti-tumor, and metabolic regulatory activities. These effects are linked to direct or indirect interactions with multiple pathways involving key molecules upstream and downstream. Conclusion: While ENG shows promise, its development requires further exploration. Future studies should focus on elucidating its mechanisms of action, identifying targets through clinical studies, and optimizing compounds for drug development. These research directions are crucial for advancing the development and application of flavonoids. This review underscores the significant research potential of ENG, paving the way for its application in diverse clinical settings.

1 April 2024 in International Journal of General Medicine
Verified
Journal Article
Open access
PDF file
XCXin Chen
Xin Chen
XZXing Zhong
Xing Zhong
DLDan Luo
Dan Luo
YLYuhua Lei
Yuhua Lei
HHHuang Huang
Huang Huang
Background: Heart failure (HF) is a chronic disease with a poor prognosis, making it extremely important to assess the prognosis of patients with HF for accurate treatment. Secreted modular calcium-binding protein 2 (SMOC2) is a cysteine-rich acidic secreted protein that plays a pathophysiological role in many diseases, including regulation of vascular growth factor activity. It has previously been found that SMOC2 plays an essential role in cardiac fibrosis in our previous preclinical study, but whether it can be used as a clinical marker in heart failure patients remains unclear. The purpose of this research was to evaluate the correlation between plasma levels of SMOC2 and the prognosis for individuals with HF. Methods: HF patients diagnosed with ischemic cardiomyopathy were enrolled from January to December 2021. Baseline plasma levels of SMOC2 were measured after demographic and clinical features were collected. Linear and nonlinear multivariate Cox regression models were used to determine the association between plasma SMOC2 and patient outcomes during follow-up. All analysis was performed using SPSS, EmpowerStats, and R software. Results: The study included 188 patients, and the average follow-up time was 489.5± 88.3 days. The plasma SMOC2 concentrations were positively correlated with N-terminal pro-B-type Natriuretic Peptide (NT-proBNP), left ventricular end-diastolic diameter (LVEDd), and length of hospital stay and were negatively correlated with left ventricular ejection fraction (LVEF) at baseline. A total of 53 patients (28.2%) were rehospitalized due to cardiac deterioration, 14 (7.4%) died, and 37 (19.7%) developed malignant arrhythmias. A fully adjusted multivariate COX regression model showed that SMOC2 is associated with readmission (HR = 1.02, 95% CI:1.012– 1.655). A significant increase in rehospitalization risk was observed in group Q2 (HR =1.064, 95% CI: 1.037, 3.662, p=0.005) and group Q3 (HR =1.085, 95% CI:1.086, 3.792, p=0.009) in comparison with group Q1. The p for trend also shows a linear correlation across the three models (P < 0.001). SMOC2 was associated with the severity of HF in patients, but not with all-cause deaths and arrhythmias during follow-up. Conclusion: Plasma SMOC2 is associated with the severity of HF and readmission rate, and is a good predictor of the risk of readmission in patients.

1 March 2026 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
LYLu Ye
Lu Ye
PTPusong Tang
Pusong Tang
HWHaixu Wan
Haixu Wan
XZXing Zhong
Xing Zhong
XCXin Chen
Xin Chen
HHHuang Huang
Huang Huang
Semaglutide (SEM), a GLP-1 receptor agonist (GLP-1RA), is commonly used to manage blood glucose and weight in type 2 diabetes mellituspatients (T2DM). Research indicates that SEM protects the kidneys and heart by slowing estimated glomerular filtration rate (eGFR) decline, reducing proteinuria, enhancing cardiac outcomes, and lowering cardiovascular risk. These benefits are linked to various mechanisms, including reduced oxidative stress and inflammation, anti-fibrotic effects, modulation of metabolism, inhibition of apoptosis, suppression of ferroptosis, and improved mitochondrial function for energy regulation. However, some studies have also found that SEM may potentially lead to renal impairment or even promote the progression of cardiorenal syndrome (CRS). Due to conflicting results, more animal studies and large-scale clinical trials are needed to understand SEM’s effects on CRS and its side effects, aiding in personalized treatment strategies. This review summarizes the functions and mechanisms of SEM in CRS, and highlights current research limitations and proposed directions for future studies.

22 October 2024 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
RHRui Huang
Rui Huang
XZXing Zhong
Xing Zhong
PTPusong Tang
Pusong Tang
QHQingning Huang
Qingning Huang
XCXin Chen
Xin Chen
YLYuhua Lei
Yuhua Lei
Acute myocardial ischemia/reperfusion injury (MIRI) with complicated mechanisms contributes to a high risk of ventricular arrhythmia, high lethality, and even sudden death. In vitro, Fraxinellone (FRA) exhibits an array of biologic activities and may possess cardioprotective effects. However, no relevant studies have examined FRA's protective potential against MIRI and related ventricular arrhythmias. The present study was undertaken to determine the effectiveness of FRA on MIRI and ventricular fibrillation (VF) susceptibility in rats and to elucidate the underlying mechanisms. 48 healthy male Sprague-Dawley (SD) rats were randomly divided into the following four groups: Sham+vehicle(n=12), Sham+FRA(n=12), I/R+vehicle(n=12) and I/R+FRA(n=12). Histopathology, electrophysiological examination, HRV analysis in combination with molecular biology were used to investigate the therapeutic benefits of FRA on cardiac injury and VF susceptibility during myocardial IR. Finally, the potential mechanism by which FRA protects myocardium from MIRI was explored. Pretreatment with FRA ameliorated myocardial fibrosis after MIRI in vivo, alleviated myocardial injury, inflammation, oxidative stress and apoptosis in vivo and in vitro, thereby protecting myocardium from MIRI injury. In addition, FRA administration could improve HRV, prolong ventricular effective refractory period (ERP) and action potential duration (APD), attenuate VF induction rate, and contribute to improving ventricular sympathetic nerve remodeling and ion channel remodeling. Mechanistically, FRA may reduce MIRI via the PI3K/AKT pathway. FRA may exert cardioprotective effects during MIRI by inhibiting myocardial inflammation, oxidative stress and apoptosis, and decrease VF susceptibility by improving sympathetic remodeling and ion channel remodeling, which might represent a potential therapeutic strategy for attenuation of MIRI.

3 April 2020 in Research Square
Verified
Preprint
Open access
PDF file
XCXin Chen
Xin Chen
PCPeng Chen
Peng Chen
DDDodji Kossi Djakpo
Dodji Kossi Djakpo
YLYan Lin
Yan Lin
RZRong Zhang
Rong Zhang
ZWZhi-Quan Wang
Zhi-Quan Wang
Background: Since December 2019, a severe novel coronavirus (SARS-CoV-2) infection (Coronavirus Disease 2019,COVID-19) has occurred in Wuhan, China, and has rapidly spread to the country and around the world. This study intends to investigate the epidemiological and clinical characteristics of patients with COVID-19 in a surrounding city of Wuhan.Methods: A retrospective study was conducted on 208 cases of COVID -19 patients from February 11, 2020 to February 29, 2020 in Xiaogan dongnan Hospital, collected basic information, history of exposure, medical history, clinical symptoms, laboratory indicators and pulmonary imaging Data, and analyzed the epidemiological and clinical characteristics of all patients. According to the clinical classification criteria, 208 patients were divided into light group and ordinary group, and the epidemiological and clinical characteristics of the two groups were compared.Results: Among 208 patients in this study, with a median age of 50.5 years (IQR,36-64.7,range,10-91 years), among which 107 (51.4%) were males and 101 (48.6%) were females. 51 (24.5%) had a clear exposure to COVID-19 infection within 2 weeks before admission, and 40 (19.2%) had a history of residence or exposure in Wuhan within 2 weeks before admission. Among all the patients, there were 16 (7.7%) with pulmonary diseases, 41 (19.7%) with hypertension, 11 (5.3%) with coronary heart disease, 13 (6.3%) with diabetes, 12(5.8%) with a history of alcohol consumption, and 12(5.8%) with a history of smoking. Among all clinical symptoms, 146 cases (70.2%) of fever, the highest temperature range was 37.3℃-41℃ before admission, 115 (55.3%) cases of cough, and 57 (27.4%) cases of chest tightness, 47 (22.6%) cases of fatigue, 28 (13.5%) cases of inappetence, 9 (4.3%) cases of diarrhea, 7 (3.4%) cases of nasal congestion or runny nose , and 5 ( 2.4%) cases of pharyngalgia. Analysis of the laboratory results of 208 patients showed that 42 (20.2%) cases had decreased white blood cell count, and 61 (29.3%) cases had decreased lymphocyte count. There were 154 (74%) cases with elevated CRP, 50 (24%) cases with elevated fasting blood glucose, and 23 (11.1%) cases with elevated LDH (>245U/L). The comparison of clinical characteristics between the light group and the common group showed that the median age of the light group was 44.8 years (IQR 30-58), the median age of the common group was 53.1 years (IQR 38.8-67) (P<0.01). The symptoms of fever [53(80.3%) vs 93(65.5%),P<0.05], fatigue [53(80.3%) vs 93(65.5%),P<0.05] and inappetence [4(6.1%) vs 24(16.9%),P<0.05] in the light group were less than those in the common group. The white blood cell count (5.48 vs 6.37, P<0.05), lymphocyte count (1.40 vs 1.61, P<0.05) and HDL-C (1.5 vs 1.3, P<0.05) of the common group were lower than that of the light group, while CRP (26.5 vs 22.1, P<0.01), AST (22.9 vs 18.5, P<0.05), fasting blood glucose (5.8 vs 5.6, P<0.05), LDH (196.8 vs 157.9, P<0.001) of the common group were higher than that of the light group.Conclusion: COVID-19 infection is mainly in middle-aged and elderly patients, patients with other diseases are more susceptible to infection. The main symptoms of COVID-19 infection were fever, cough, chest tightness, fatigue, and inappetence. Decreased lymphocyte count, increased CRP concentration, increased LDH concentration and decreased HDL-C concentration were the laboratory features of COVID-19 infection, and were important indicators to assess the severity of COVID-19 disease.